Enantioselective pharmacokinetic and pharmacodynamic properties of carvedilol in spontaneously hypertensive rats: Focus on blood pressure variability

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 385, Issue 3, 2012, Pages 325-335

  Bertera, Facundo Martín ^a   Del Mauro, Julieta Sofía ^a   Chiappetta, Diego ^a   Polizio, Ariel Héctor ^a   Buontempo, Fabián ^b   Taira, Carlos Alberto ^a   Höcht, Christian ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Hospital de Pediatria SAMIC Prof Dr Juan P Garrahan   (Argentina)

Author keywords

Blood pressure variability; Carvedilol; Pharmacokinetic pharmacodynamic modelling; Pharmacokinetics; Spontaneously hypertensive rats; Sympathetic vascular activity

Indexed keywords

CARVEDILOL; HYPERTENSIVE AGENT;

ADRENERGIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE VARIABILITY; BLOOD SAMPLING; BRADYCARDIA; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; DRUG MECHANISM; ENANTIOSELECTIVITY; EXPERIMENTAL ANIMAL; HEART RATE; HYPERTENSION; MALE; NONHUMAN; RACEMIC MIXTURE; RAT; WISTAR KYOTO RAT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARBAZOLES; HEART RATE; HYPERTENSION; MALE; MODELS, BIOLOGICAL; PROPANOLAMINES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; STEREOISOMERISM;

EID: 84862906614     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-011-0698-7     Document Type: Article

References (40)

1. Abboud FM (1982) The sympathetic system in hypertension. State of the art review. Hypertension 4:208-225
2. Adams MA, Bobik A, Korner PI (1989) Differential development of vascular and cardiac hypertrophy in genetic hypertension. Relation to sympathetic function. Hypertension 14:191-202 (Pubitemid 19205174)
3. Aimone LD (2005) Overview of pharmacokinetics. Curr Protoc Pharmacol 7(1):1-26
4. Bartsch W, Sponer G, Strein K, Müller-Beckmann B, Kling L, Böhm E, Martin U, Borbe HO (1990) Pharmacological characteristics of the stereoisomers of carvedilol. Eur J Clin Pharmacol 38(suppl 2):S104-S107 (Pubitemid 20183992)
5. Bertera FM, Di Verniero CA, Mayer MA, Bramuglia GF, Taira CA, Höcht C (2009) Is urethane-chloralose anaesthesia appropriate for pharmacokinetic- pharmacodynamic assessment? Studies with carvedilol. J Pharmacol Toxicol Methods 59:13-20
6. Bertera FM, Di Verniero CA, Mayer MA, Chiappetta D, Buontempo F, Polizio AH, Taira CA, Höcht C (2011) Pharmacokinetic and pharmacodynamic properties of carvedilol in fructose hyperten-sive rats. Xenobiotica (in press)
7. D'Argenio DZ, Schumitzky A (1997) ADAPT II User's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles
8. Di Verniero CA, Bertera F, Buontempo F, Bernabeu E, Chiappetta D, Mayer MA, Bramuglia GF, Taira CA, Höcht C (2010) Enantio-selective pharmacokinetic-pharmacodynamic modelling of carve-dilol in a N-nitro-L-arginine methyl ester rat model of secondary hypertension. J Pharm Pharmacol 62:890-900
9. Fazan R Jr, Huber DA, Silva CA, Dias da Silva VJ, Salgado MC, Salgado HC (2008) Sildenafil acts on the central nervous system increasing sympathetic activity. J Appl Physiol 104:1683-9
10. Fujimaki M (1992) Stereoselective disposition and tissue distribution ofcarvedilol enantiomers in rats. Chirality 4:148-154
11. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York
12. Hashimoto H, Kanda A, Hubo H, TanakaM(1991) Features ofthe acute hypotensive action of carvedilol and its ameliorating effect on myocardial ischemia. J Cardiovasc Pharmacol 18(Suppl 4):S22-S28
13. Höcht C, Di Verniero C, Opezzo JA, Bramuglia GF, Taira CA (2006) Pharmacokinetic-pharmacodynamic (PK-PD) modeling of car-diovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study. Naunyn Schmiedebergs Arch Pharmacol 373:310-318 (Pubitemid 43999782)
14. Höcht C, Mayer MA, Opezzo JAW, Bertera FM, Taira CA (2008) Pharmacokinetic-pharmacodynamic modeling of antihypertensive drugs: from basic research to clinical practice. Curr Hypertens Rev 4:289-302
15. Höcht C, Bertera FM, Taira CA (2010a) Importance ofblood pressure variability in the assessment of cardiovascular risk and benefits of antihypertensive therapy Expert Rev Clin Pharmacol 3:617-621
16. Höcht C, Bertera FM, Mayer MA, Taira CA (2010b) Issues in drug metabolism of major antihypertensive drugs: beta-blockers, calcium channel antagonists and angiotensin receptor blockers. Expert Opin Drug Metab Toxicol 6:199-211
17. Isanta JR, Lasheras B, Fos D, Cenarruzabeitia E (1987) Comparative diltiazem plasma clearance in normotensive and hypertensive rats. J Pharm Sci 76:862-865 (Pubitemid 18006831)
18. Ishida K, Taira S, Morishita H, Kayano Y, Taguchi M, Hashimoto Y (2008) Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes. Biol Pharm Bull 31:1297-1300 (Pubitemid 351871190)
19. Jacob HJ, Alper RH, Brody J (1989) Lability ofarterial pressure after baroreceptor denervation is not pressure dependent. Hypertension 14:501-510 (Pubitemid 19270515)
20. Janssen BJ, Oosting J, Slaaf DW, Persson PB, Struijker-Boudier HA (1995) Hemodynamic basis of oscillations in systemic arterial pressure in conscious rats. Am J Physiol 269:H62-H71
21. Miao CY, Xie HH, Zhan LS, Su DF (2006) Blood pressure variability is more important than blood pressure level in determination of end-organ damage in rats. J Hypertens 24:1125-1135
22. Neugebauer G, Akpan W, Kaufmann B, Reiff K (1990) Stereo-selective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Eur J Clin Pharmacol 38(suppl 2):S108-S111 (Pubitemid 20183993)
23. Nichols AJ, Gellai M, Ruffolo RR Jr (1991) Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundam Clin Pharmacol 5:25-38
24. Oosting J, Struijker-Boudier HA, Janssen BJ (1997) Circadian and ultradian control of cardiac output in spontaneous hypertension in rats. Am J Physiol 273:H66-H75
25. Parati G (2005) Blood pressure variability: its measurement and significance in hypertension. J Hypertens 23(suppl 1):S19-S25
26. Phuong NT, Lee BJ, Choi JK, Kang JS, Kwon KI (2004) Enantioselective pharmacokinetics of carvedilol in human volunteers. Arch Pharm Res 27:973-977
27. Pintérová M, Kuneš J, Zicha J (2011) Altered neural and vascular mechanisms in hypertension. Physiol Res 60:381-402
28. Pladys P, Lahaie I, Cambonie G, Thibault G, Lê NL, Abran D, Nuyt AM (2004) Role of brain and peripheral angiotensin II in hypertension and altered arterial baroreflex programmed during fetal life in rat. Pediatr Res 55:1042-1049 (Pubitemid 38661798)
29. Ponchon P, Elghozi JL (1997) Contribution of humoral systems to the short-term variability ofblood pressure after severe hemorrhage. Am J Physiol 273:R58-R69
30. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, DahlöfB, Poulter NR, Sever PS, ASCOT-BPLA and MRC Trial Investigators (2010) Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 9:469-480
31. Ruffolo RR Jr, Gellai M, Hieble JP, Willette RN, Nichols AJ (1990) The pharmacology of carvedilol. Eur J Clin Pharmacol 38(suppl 2):S82-S88 (Pubitemid 20183988)
32. Souza HC, Martins-Pinge MC, Dias da Silva VJ, Borghi-Silva A, Gastaldi AC, Blanco JH, Tezini GC (2008) Heart rate and arterial pressure variability in the experimental renovascular hyperten-sion model in rats. Auton Neurosci 139:38-45
33. Stahl E, Mutschler E, Baumgartner U, Spahn-Langguth H (1993) Carvedilol stereopharmacokinetics in rats: affinities to blood constituents and tissues. Arch Pharm (Weinheim) 326:529-533 (Pubitemid 23287141)
34. Stauss HM (2007) Identification ofblood pressure control mechanisms by power spectral analysis. Clin Exp Pharmacol Physiol 34:362-388
35. Su DF, Miao CY (2001) Blood pressure variability and organ damage. Clin Exp Pharmacol Physiol 28:709-715
36. Terao N, Shen DD (1983) Alterations in serum protein binding and pharmacokinetics of L-propranolol in the rat elicited by the presence of an indwelling venous catheter. J Pharmacol Exp Ther 227:369-375 (Pubitemid 14241128)
37. Tomlinson B, Dalal JJ, Huang J, Low LP, Park CG, Rahman AR, Reyes EB, Soenarta AA, Heagerty A, Follath F (2011) The role of ß-blockers in the management of hypertension: an Asian perspective. Curr Med Res Opin 27:1021-1033
38. Tsoporis J, Leenen FH (1988) Effect ofarterial vasodilators on cardiac hypertrophy and sympathetic activity in rats. Hypertension 11:376-386
39. Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64:1147-1461
40. Zhou HH, Wood AJ (1995) Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 57:518-524